Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing
- 27 August 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (12) , 2121-2130
Abstract
Objectives: Assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and immunity is cornerstones in the fight against COVID-19 pandemic. For pandemic control, reliable assays for the detection of anti-SARS-CoV-2 antibodies are required. This pilot external quality assessment (EQA) scheme aimed to independently assess the participants’ clinical performance of anti-SARS-CoV-2 testing, to identify shortcomings in clinical practice and to evaluate the suitability of the scheme format. Methods: The EQA scheme consisted of eight serum samples with variable reactivity against SARS-CoV-2 intended for the analysis of anti-SARS-CoV-2 immunoglobulin (Ig)G, IgA, and IgM antibodies. Laboratories reported: (1) results for each sample and the respective method, (2) raw data from replicate testing of each sample. Results: The 16 selected pilot EQA participants reported 294 interpreted results and 796 raw data results from replicate testing. The overall error rate for the anti-SARS-CoV-2 IgG, IgA, and IgM tests was 2.7, 6.9, and 16.7%, respectively. While the overall diagnostic specificity was rated as very high, sensitivity rates between 67 and 98% indicate considerable quality differences between the manufacturers, especially for IgA and IgM. Conclusions: Even the results reported by the small number of participants indicate a very heterogeneous landscape of anti-SARS-CoV-2 serological testing. Differences of available tests and the individual performance of laboratories result in a success rate of 57.1% with one laboratory succeeding for all three antibody-classes. These results are an incentive for laboratories to participate in upcoming open EQA schemes that are needed to achieve a harmonization of test results and to improve serological testing.Keywords
This publication has 33 references indexed in Scilit:
- Improvement in serological diagnosis of pertussis by external quality assessmentJournal of Medical Microbiology, 2019
- Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA)Clinical Chemistry and Laboratory Medicine (CCLM), 2017
- Thirteen Years of an International External Quality Assessment Scheme for Genotyping: Results and RecommendationsClinical Chemistry, 2016
- Statistical approach for optimization of external quality assurance (EQA) studies of molecular and serological viral diagnosticsClinical Chemistry and Laboratory Medicine (CCLM), 2016
- Results of the National External Quality Assessment for Toxoplasmosis Serological Testing in ChinaPLOS ONE, 2015
- Proficiency Testing/External Quality Assessment: Current Challenges and Future DirectionsClinical Chemistry, 2011
- First external quality assurance of antibody diagnostic for SARS-new coronavirusJournal of Clinical Virology, 2005
- Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus InfectionThe Journal of Infectious Diseases, 2004
- Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS CoronavirusClinical and Vaccine Immunology, 2004
- Profile of Specific Antibodies to the SARS-Associated CoronavirusNew England Journal of Medicine, 2003